Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Cambios rev. méd ; 20(1): 21-25, 30 junio 2021. tabs.
Article in Spanish | LILACS | ID: biblio-1292703

ABSTRACT

INTRODUCCIÓN. La apendicitis aguda es una patología pediátrica quirúrgica que en su fase complicada requiere uso de antibióticos en el postoperatorio; encontrar la mejor opción como experiencia local, fue necesario. OBJETIVO. Comparar un esquema de antibioticoterapia triple vs un doble respecto a variables: demográficas, clínicas y de costos en pacientes pediátricos con apendicitis complicada. MATERIALES y MÉTODOS. Estudio analítico transversal. Población de 133 pacientes y una muestra de 93, operados por apendicitis complicada; 58 recibieron ampicilina + metronidazol + gentamicina y 35 ceftriaxona + metronidazol. Se comparó las variables: estadía hospitalaria, complicaciones y costo monetario de cada esquema. Se realizó en la Unidad de Cirugía Pediátrica del Hospital de Especialidades Carlos Andrade Marín, en el periodo enero de 2017 a octubre de 2018. Los datos fueron analizados con R-Studio 1.8.366 para Windows. RESULTADOS. No hubo diferencia estadística con respecto a: estadía hospitalaria (p=0,261); complicaciones como infección del sitio quirúrgico (p=0,196), re-intervención quirúrgica (p=0,653) y costo (p=0,059). CONCLUSIÓN. Se comparó el esquema de antibioticoterapia triple vs un doble, utilizados en apendicitis complicada en pediatría. No se encontró diferencias estadísticamente significativas en este reporte preliminar, con la diferencia de que con el esquema doble la frecuencia de administración fue menor y se evitó la exposición a los efectos colaterales de los aminoglicósidos.


INTRODUCTION. Acute appendicitis is a pediatric surgical pathology that in its complicated phase requires the use of antibiotics during the postoperative period; finding the best option as local experience was a must. OBJECTIVE. Compare a triple vs a double antibiotic therapy scheme respect demographic, clinical and cost variables in pediatric patients whit complicated apendicitis. MATERIALS AND METHODS. Cross-sectional analytical study. Population of 133 patients and sample of 93, with complicated appendicitis; 58 received ampicillin + metronidazole + gentamicin and 35 ceftriaxone + metronidazole. The following variables were compared; hospital stay, complications and monetary cost of each scheme. It was performed in the Pediatric Surgery Unit of the Hospital of Specialties Carlos Andrade Marin, during january 2017, through october 2018. The data were analyzed with R-Studio 1.8.366 for Windows. RESULTS. There was no statistical difference regarding hospital stay (p=0.261); complications such as surgical site infection (p=0.196), re-surgical intervention (p=0.653); nor cost (p=0.059). CONCLUSION. Triple vs. Double antibiotic therapy scheme used in complicated appendicitis in pediatrics was compared. No statistically significant differences were found in this preliminary report, how ever with the double scheme the frequency of administration was lower and exposure to side effects of aminoglycosides was avoided.


Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Appendicitis/complications , Gentamicins , Cephalexin , Ampicillin , Metronidazole , Anti-Bacterial Agents/therapeutic use , Pediatrics , Postoperative Complications , General Surgery , Cost-Benefit Analysis
2.
Iatreia ; 31(2): 207-215, ene.-jun. 2018. tab
Article in Spanish | LILACS | ID: biblio-1039994

ABSTRACT

RESUMEN En esta edición de la Ronda Clínica y Epidemiológica presentamos cuatro artículos que desde la práctica clínica consideramos de especial interés. Wan-Chuan, et al., contribuyen con una revisión sistemática y meta-análisis a la discusión de las metas ideales de presión arterial en pacientes hipertensos, esta vez desde una perspectiva diferente: impacto de metas intensivas de presión arterial en pacientes no diabéticos con enfermedad renal crónica. Adicionalmente, Valent, et al., realizan un ensayo clínico aleatorizado para estudiar el efecto de la profilaxis antibiótica postoperatoria en el riesgo de infección de sitio operatorio en gestantes obesas llevadas a cesárea. Por otro lado, Miro, et al., siguen una cohorte de pacientes con falla cardíaca aguda para probar la posibilidad de predecir la mortalidad usando información que puede obtenerse desde el ingreso a urgencias. Para finalizar, Andersson, et al., traen una propuesta prometedora para mejorar el enfoque diagnóstico de pacientes con sospecha de apendicitis y el impacto en el uso de recursos en esta población.


SUMMARY In this edition of the clinical and epidemiological round, we present four articles that we consider relevant from a clinical point of view. Wan-Chuan, et al., contribute with a systematic review and meta-analysis to the discussion of the ideal blood pressure goals, this time from a different perspective: impact of intensive blood pressure goals in non-diabetic patients with chronic kidney disease. In addition, Valent et al., performed a randomized clinical trial to study the effect of the post-operatory prophylaxis in the risk of infection of the surgical site in obese pregnant women underwent a cesarean section. On the other hand, Miro et al. followed a cohort of patients with acute heart failure to prove the possibility to predict mortality using information which can be taken in the emergency room. To conclude, Andersson et al., bring a promising proposal to improve the diagnostic approach in patients in which an appendicitis is suspected, as well as its impact in the use of the resources.


Subject(s)
Humans , Appendicitis
3.
Evid. odontol. clín ; 2(1): 16-20, ene.-jun. 2016. tab, graf
Article in Spanish | LILACS | ID: biblio-1000013

ABSTRACT

Introducción: La presente investigación tuvo por objeto determinar la eficacia de la cefalexina, la terramicina y del ácido cítrico como bioacondicionadores en los niveles de cobertura radicular y de inserción en pacientes con recesión gingival clase II de Miller intervenidos a colgajo desplazado coronalmente. Materiales y método: Se trata de un ensayo clínico randomizado intergrupo, con pretest y postest múltiple, se conformaron 3 grupos: dos experimentales (1 y 2) que recibieron respectivamente la cefalexina y la terramicina; y un grupo control en el que se le aplicó ácido cítrico, como bioacondicionadores cementarios. Cada grupo estuvo constituido por 20 recesiones gingivales clase II de Miller, con indicación básica de colgajo desplazado coronalmente, los datos se evluaron mediante las pruebas Chi Cuadrado de Pearson y ANOVA. Resultados: No hubo diferencia estadística significativa en el efecto de la cefalexina, la terramicina y en el ácido cítrico en el nivel de cobertura radicular a los 30 días. El contraste ANOVA mostró en cambio, a los 60 días una diferencia estadística significativa, en el efecto de dichos bioacondicionadores en la ganancia de inserción. Conclusiones:El uso de bioacondicionares genera resultados significativos en el manejo de recesiones gingivales, siendo más afectivos a largo plazo. (AU)


Introduction: The present study was designed to determine the efficacy of cefalexin, the terramycin and citric acid as bioconditioners in root coverage and levels of insertion in patients with class II Miller gingival recession intervened to displaced face flap. Materials and method: is of a trial clinical randomized Intergroup, with pretest and posttest multiple, is formed 3 groups: two experimental (1 and 2) that received respectively the cephalexin and the terramycin; and a group control in which is it applied acid citric, as bioconditioners inserted. Each group was made up of 20 gingival recessions class Miller II, with basic indication of flap displaced face, the data is evluaron using ANOVA and Pearson Chi square tests. Results: There was No statistical significant difference in the effect of cefalexin, the terramycin and citric acid at the level of root coverage within 30 days. The contrast ANOVA showed instead, to them 60 days a difference statistical significant, in the effect of such bioconditioners in the gain of inclusion. Conclusions: the use of bioconditioners generates results significant at the handling of recessions gingival, being more affec tive to long term. (AU)


Subject(s)
Humans , Oxytetracycline/therapeutic use , Cephalexin/therapeutic use , Citric Acid/therapeutic use , Gingival Recession/therapy , Clinical Trial
4.
Braz. j. pharm. sci ; 51(2): 383-392, Apr.-June 2015. tab, ilus
Article in English | LILACS | ID: lil-755062

ABSTRACT

The aim of the present study was to assess the bioequivalence of two cephalexin tablet formulations available in the Brazilian market (product A as reference formulation and product B as test formulation). Dissolution efficiency (DE%) was calculated for both formulations to evaluate their in vitrobiopharmaceutical features. The oral bioequivalence study was performed in twenty-four healthy volunteers in a crossover design. Single oral dose (tablet containing 500 mg of cephalexin) of each product was administered with two weeks of washout period. Urinary concentrations of cephalexin were measured by high-performance liquid chromatography (HPLC) method and pharmacokinetics parameters were estimated by urinary excretion data. The bioequivalence was determined by the following parameters: the cumulative amount of cephalexin excreted in the urine, the total amount of cephalexin excreted in the urine and the maximum urinary excretion rate of cephalexin. DE values of immediate-release cephalexin tablets (500 mg) were 68.69±4.18% for product A and 71.03±6.63% for product B. Regarding the dissolution test of the two brands (A and B) analysed, both were in compliance with the official pharmacopeial specifications, since the dissolution of both formulations was superior to 80% of the amount declared in the label after 45 minutes of test (A=92.09%±1.84; B=92.84%±1.08). The results obtained indicated that the products A and B are pharmaceutical equivalents. Confidence intervals for the pharmacokinetic parameters were in compliance with the international standards, indicating that products A and B can be considered bioequivalents and, therefore, interchangeable...


O objetivo do presente estudo foi avaliar a bioequivalência de duas formulações de cefalexina disponíveis no mercado brasileiro (produto A como formulação referência e produto B como formulação teste). A eficiência de dissolução (DE%) foi calculada para ambas as formulações para avaliar suas características biofarmacêuticas. O estudo de bioequivalência oral foi realizado em vinte e quatro voluntários sadios utilizando um desenho cruzado. Uma dose oral única (comprimido contendo 500 mg de cefalexina) de cada produto foi administrada com um período de washout de duas semanas. Concentrações urinárias de cefalexina foram mensuradas por método de cromatografia líquida de alta eficiência (CLAE) e os parâmetros farmacocinéticos foram estimados por dados de excreção urinária. A bioequivalência foi determinada pelos seguintes parâmetros: quantidade acumulada da cefalexina excretada na urina, quantidade total da cefalexina excretada na urina e a taxa de excreção máxima da cefalexina. Os valores de DE dos comprimidos de liberação imediata de cefalexina (500 mg) foram 68,69±4,18% para o produto A e de 71,03±6,63% para o produto B. Com relação ao teste de dissolução das duas marcas analisadas (A e B), ambas apresentaram-se de acordo com as especificações farmacopéicas, uma vez que a dissolução de ambas formulações foi superior a 80% da quantidade declarada após 45 minutos de teste (A=92,09%±1,84; B=92,84% ±1,08). Os resultados obtidos indicaram que os produtos A e B são equivalentes farmacêuticos. Os intervalos de confiança para os parâmetros farmacocinéticos estavam de acordo com os padrões internacionais, demonstrando que os produtos A e B podem ser considerados bioequivalentes e, portanto, intercambiáveis...


Subject(s)
Humans , Cephalexin/pharmacokinetics , Cephalexin/pharmacology , Chromatography, High Pressure Liquid , Therapeutic Equivalency , Urine/chemistry
5.
Article in Portuguese | LILACS | ID: lil-560257

ABSTRACT

Com o avanço da tecnologia e das pesquisas envolvendo liberação de fármacos, modernização de testes e maior ênfase da previsibilidade de efeitos terapêuticos por meio dos testes in vitro, os testes de dissolução e os estudos de perfis de dissolução têm ganhado cada vez mais importância. Apesar de terem sido introduzidos inicialmente como uma forma de caracterizar o perfil de liberação de fármacos pouco solúveis, atualmente os testes de dissolução fazem parte das monografias de quase todas as formas farmacêuticas sólidas orais. Este trabalho teve como objetivo estudar o perfil de dissolução (porcentagem de fármaco dissolvido versus tempo) dos medicamentos de referência, genérico e similar contendo cefalexina 500 mg na forma farmacêutica de cápsulas. Foram analisadas três especialidades farmacêuticas (referência, genérico e similar), os quais foram submetidos ao teste de dissolução e perfil de dissolução in vitro. Os resultados obtidos no teste de dissolução permitem concluir que as amostras encontraram-se de acordo com as especificações e o perfil de dissolução deste medicamento, nesta forma farmacêutica, é considerado de dissolução rápida (85% de fármaco dissolvido em 15 minutos). Portanto, existe uma grande semelhança entre as curvas obtidas, o que sugere que se trata de equivalentes farmacêuticos.


With recent advances in technology and research into drug delivery, the modernization of tests and greater emphasis on the predictability of therapeutic effect by means of in vitro tests, the dissolution test and the study of dissolution profiles are gaining more and more importance. Though introduced initially as a way of characterizing the release profile of poorly soluble drugs, dissolution tests are currently part of pharmacopoeial monographs on almost all the oral solid pharmaceutical forms. The objective of this study was to determine the dissolution profile (percent drug dissolved versus time) of the pioneer brand, generic and similar pharmaceutical capsules containing 500mg cephalexin. Three pharmaceutical brands (reference, generic and similar) were subjected to the dissolution test and in vitro dissolution profiles were recorded. From the results of the dissolution test, it was concluded that the samples met the acceptance criterion, as no difference was observed in the percentage of the drug dissolved in a standard time. The dissolution profile indicated that this medicine, in this pharmaceutical form, dissolves readily (85% of the drug dissolved in 15 minutes) and the curves showed great similarity, suggesting that the 3 brands are pharmaceutically equivalent.


Subject(s)
Humans , Capsules , Cephalexin/pharmacokinetics , Drugs, Generic , Reference Drugs , Similar Drugs
SELECTION OF CITATIONS
SEARCH DETAIL